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Background   Bone morphogenetic proteins (BMPs) 
have the potential to improve clinical outcome after hip 
revision surgery by improving graft incorporation and 
implant ﬁxation. However, impaction of cancellous bone 
grafts and TCP/HA bone substitute mixed with OP-1 
device in a bone chamber in goats in a previous study 
led to reduced ﬁbrous tissue ingrowth after 4 weeks. 
New bone formation was not promoted by OP-1. In the 
current study we examined whether this reduction rep-
resented a ﬁnal loss of ingrowth or was just a delay, and 
whether the reduction can be overcome and ultimately 
results in a better late ingrowth.
Methods   Bone chambers with impacted allografts 
and impacted TCP/HA granules mixed with 2 doses of 
OP-1 device were implanted in proximal medial goat 
tibias. Impacted allografts and TCP/HA not treated 
with OP-1  served as controls. After 8 weeks, the incor-
poration was evaluated using histology and histomor-
phometry. 
Results   Histology revealed evidence of bone graft 
incorporation, which proceeded in a similar way in both 
allografts and TCP/HA, with and without the addition 
of OP-1. After 8 weeks, no difference in bone ingrowth 
was found between the OP-1 groups and their controls. 
It was only in the allografts that the addition of OP-1 
resulted in more ﬁbrous tissue ingrowth.
Interpretation   We conclude that the previously 
observed delay in ﬁbrous tissue ingrowth can be only 
partially overcome.
■
Growth factor-enhanced allograft incorporation 
could improve clinical outcome after hip revi-
sion surgery by accelerating new hip formation 
and thereby improving implant stability (Lind et 
al. 2001). Bone morphogenetic proteins (BMPs) 
provide an opportunity to achieve faster and more 
extensive remodeling (Cook et al. 2000). They 
stimulate bone formation (Cook et al. 1998) and 
graft remodeling (Tägil et al. 2000). However, 
also BMP stimulated bone resorption has  been 
observed both in vitro and in vivo (Kanatani et al. 
1995, Kaneko et al. 2000) and in vivo (Laursen et 
al. 1999, Jensen et al. 2002, McGee et al. 2004). 
Accelerated resorption may have negative conse-
quences for bone impaction grafting, since resorp-
tion before the formation of bone may compromise 
implant ﬁxation. One solution would be an osteo-
conductive material providing initial stability after 
reconstruction (Oonishi 1991, Oonishi et al. 1997, 
Tägil et al. 2003). The role of BMPs in hip revision 
surgery might then be to serve as a promotor of 
bone formation in combination with a slow resorb-
ing or unresorbable graft material (Aspenberg and 
Åstrand 2002, Åstrand and Aspenberg 2002).
In a previous study, we investigated the early 
effects of OP-1 device (OP-1 attached to a col-
lagen carrier) on the incorporation of impacted 
morselized cancellous bone and tri-calcium phos-
phate/hydroxy-apatite (TCP/HA) in an unloaded 
bone chamber in goats (Hannink et al. 2006). After 
4 weeks, new bone formation was not promoted 
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of accelerated resorption. However, a dose-related 
inhibition of vascularization and ﬁbrous tissue 
ingrowth was found. 
In general, in impacted bone grafts, the migration 
of cells within the allograft is compromized and 
vascularization is delayed for several weeks (Ling 
et al. 1993, Buma et al. 1996, Schreurs et al. 1996). 
In an unloaded bone chamber in rats, at 6 weeks 
the bone ingrowth into densely impacted allografts 
was delayed relative to bone ingrowth in allografts 
that had not been impacted (Tägil and Aspenberg 
1998). An impacted graft acts as a hindrance for the 
ingrowing tissue or vessels, and this effect may be 
dependent on the degree of impaction. By adding 
OP-1 solution to the impacted bone grafts in the 
same unloaded model, bone ingrowth increased 
dramatically (Tägil et al. 2000). In contrast, in 
our previous study the collagen carrier might ini-
tially have further delayed bone and ﬁbrous tissue 
ingrowth into the impacted graft material by ﬁlling 
up the space between the impacted graft material 
(Hannink et al. 2006).
Thus, although the collagen type I carrier may 
not be optimal for use in bone impaction grafting, 
in clinical cases better late ingrowth may appear 
despite an early delay (Wang et al. 2000). The 
present study was designed to determine whether 
the decrease in ingrowth represented a ﬁnal loss or 
was just a delay. If the latter, could the OP-1 device 
overcome this initial delay and did this ultimately 
result in a better late ingrowth?
Animals and methods 
Experimental design
12 mature Dutch milk goats (Capra hircus sana) 
(mean weight 47 (40–56) kg) were obtained from 
the Central Animal Laboratory, Radboud Univer-
sity Nijmegen. The goats received 3 bone chambers 
on each side in the cortical bone of the proximal 
medial tibia. The side and position of implantation 
of the 6 chambers were randomized. Two concen-
trations of OP-1 device were tested in combination 
with allografts and TCP/HA. Allografts not treated 
with OP-1 and TCP/HA served as controls (Table). 
The observation time was 8 weeks. All procedures 
were approved by the Animal Ethics Committee 
of the Radboud University Nijmegen, the Nether-
lands.
Bone conduction chamber
The bone conduction chamber (BCC) (Aspenberg 
and Wang 1993) consists of a threaded titanium 
cylinder, formed from two half-cylinders held 
together by a hexagonal closed screw cap. One end 
of the implant is screwed into the bone. The inte-
rior of the chamber has a diameter of 2 mm and a 
length of 7.5 mm. There are two ingrowth openings 
for bone ingrowth located at the bone-end of the 
chamber. 
Thus, the ingrowing tissues enter the cylindri-
cal space from the bone compartment. Originally 
developed as a rat model, the BCC was adjusted 
for use in goats (Van Der Donk et al. 2001). Since 
the tibial cortex in rats is thinner than that in goats, 
a 1 mm disk was placed in the cap of the BCC to 
provide for location of the ingrowth holes of the 
chamber to be deeper down, just at the level of the 
endosteum after the implant is screwed in (Figure 
1).
Implant materials
Cancellous allografts were obtained from the ster-
num of six donor goats. Familial bands between 
donor and recepient goats were excluded. To pre-
vent bias because of different immunologic reac-
tions, the allografts were pooled. 
Most blood and marrow was removed by rins-
ing the grafts with saline for approximately 1 min, 
leaving only a white bone structure. Rinsing was 
done using a high-pressure pulsatile lavage system 
(SurgiLav Plus; Stryker Nederland BV, Waarden-
burg, the Netherlands). The grafts were in a sieve 
during rinsing. They were stored at –80ºC until 
Overview of experimental design. Bone conduction 
chambers containing allograft and TCP/HA mixed with 
OP-1 device, and controls without the growth factor. 12 
implants in each treatment group
 Dose of OP-1 device
Treatment group (µg OP-1/mg collagen)
 
Allograft –/– 
Allograft + OP-1[1] 0.83/0.24
Allograft + OP-1[2] 2.5/0.72
TCP/HA –/– 
TCP/HA + OP-1[1] 0.83/0.24
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use. Bacterial cultures from the grafts were nega-
tive. Before implantation, the grafts were thawed 
at room temperature and cut into pieces by using 
a rongeur.
The TCP/HA particles were composed of 20% 
HA (Ca10(PO4)6(OH)2) and 80% TCP (Ca3(PO4)2) 
(BoneSave; Stryker Howmedica Osteonics, Lim-
erick, Ireland). We used granules with a diameter 
of 2–4 mm. The TCP-HA granules have a 50% 
non-interconnected macroporosity (range 300–600 
µm), which is produced by burning sacriﬁcial car-
bonaceous ﬁller during sintering. The granules are 
also microporous (range 5–80 µm) (porosity values 
obtained from Stryker Orthopaedics). Before use, 
the TCP/HA particles were crushed to ﬁt into the 
BCC and subsequently soaked in saline for 30 
min. 
Graft preparation
The rhOP-1 device (Stryker Biotech, Hopkinton, 
MA) was supplied sterile for implantation and con-
sisted of 3.5 mg recombinant human osteogenic 
protein-1 (rhOP-1) combined with 1 g of highly 
puriﬁed bovine bone-derived type I collagen.
Immediately after warming to room temperature, 
the rhOP-1 device was mixed with a preweighed 
quantity of allograft chips before impaction. The 
BCC volume is 23.56 mm3, which allowed 0.0325 
g of allograft chips and 0.0163 g of TCP/HA par-
ticles to be impacted in each implant. Two doses of 
rhOP-1 device were tested, a low-dose OP-1 (0.83 
µg/implant) and a high-dose OP-1 (2.5 µg/implant). 
The high dose (2.5 µg/implant) would correspond 
to about one OP-1 device combined with one ordi-
nary femoral head. According to the instructions 
of the manufacturer, this was the intended dose for 
bone impaction grafting. 
Impaction procedure
Impaction was performed by gradually ﬁlling the 
BCC with the allograft bone/OP-1 mixtures or 
TCP/HA particles/OP-1 mixtures. A piston of a 
slightly smaller diameter was used for impaction 
(Van Der Donk et al. 2003). The piston was guided 
by low-friction bearings, strictly limiting it to verti-
cal movement. The BCC was clamped into a cylin-
drical holder. A constant force of 40 N was kept 
on the free end of the piston for 2 min. During this 
time, ﬂuid could escape between the piston and the 
wall of the bone chamber, and the ingrowth open-
ings. The pressure applied was calculated to be 
12.5 MPa. The disk was placed on the two threaded 
half-cylinders and the hexagonal closed screw cap 
was screwed on.
Surgical technique
The goats were anesthetized by intravenous admin-
istration of sodium pentobarbital (0.5 mL/kg) and 
maintained after intubation with nitrous oxide, 
oxygen and isoﬂurane (1.5–2%). Under aseptic 
conditions, a longitudinal incision was made in the 
skin and fascia over the medial side of the proximal 
tibia. After raising the periosteum, the cortical bone 
was observed and a hole was drilled through the 
medial cortex at approximately 4 cm from the joint 
cleft using a 3.1-mm drill. The hole was tapped and 
bone debris from drilling was removed. The bone 
chamber was screwed in manually. The other bone 
chambers were placed 10 mm from the others. This 
was repeated for the other side. The subcutaneous 
layer and the skin were sutured. All animals were 
allowed unrestricted movement in their cages and 
had free access to water and food after the opera-
Figure 1. The bone conduction chamber. The chamber 
consists of two threaded half-cylinders held together by a 
cylindrical closed screw cap. There are ingrowth openings 
at the endosteal level. A 1 mm thick plate (D) was inserted 
into the cap to lower the ingrowth openings through the 
cortex. New bone (NB) and ﬁbrous tissue (FT) are shown 
growing into the graft. Unremodeled graft (GR) can be 
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tion. After the implantation procedure, the animals 
received subcutaneous ampicillin (15 mg/kg/48 h) 
three times. 
After 8 weeks, all goats were killed with an 
overdose of sodium pentobarbital. Tibias were 
removed, and the bone chambers with surrounding 
cortex were ﬁxed in 4% buffered formalin. After 1 
day, the content of the chambers was removed.
Evaluation
All specimens were ﬁxed in 4% buffered formal-
dehyde, dehydrated using ethanol, and embedded 
in polymethylmetacrylate (PMMA). They were 
decalciﬁed using 25% EDTA in 0.1 mol/L phos-
phate buffer (pH 7.4) before dehydration. The spec-
imens were cut with a microtome (Leica RM 2155; 
Leica Microsystems Nederland BV, Rijswijk, the 
Netherlands) parallel to the longitudinal axis of the 
chamber. From each specimen, a total of 5 sections 
were taken at 0, 300 and 600 µm from the center 
of the specimen, each section being 5 µm thick. 
All sections within each experimental group were 
investigated in random order. The tests were done 
blind, but it was possible to see whether a speci-
men contained allograft or TCP/HA. The sections 
were stained with hematoxylin and eosin (HE), 
Goldner-Masson trichrome, and tartrate-resis-
tant acid phosphatase (TRAP) for routine histol-
ogy. Histomorphometric analysis was performed 
by using interactive computer-controlled image 
analysis (analySIS; Soft Imaging System GmbH, 
Münster, Germany). The bone ingrowth distance 
in each slide was calculated by dividing the new 
bone area by the width of the specimen (Aspenberg 
and Wang 1993). In all specimens, marrow cavi-
ties surrounded by bone were included in the bone 
area. The total tissue ingrowth distance, which is 
the distance from the ingrowth end to the ﬁbrous 
ingrowth frontier, was measured in the same way 
as bone ingrowth. The mean of 5 sections yielded a 
value for each specimen.
Statistics
Statistical analysis was performed using a univari-
ate analysis of variance (SPSS Inc., Chicago, IL) 
with factors goat, side, position and graft type. To 
identify the group or groups that differed from the 
others, Tukey’s multiple comparison procedure was 
used. Normality and homogenity of variance were 
tested using the Kolmogorov-Smirnov test and the 
Levene test. When the assumption of normality or 
homogenity of variance was not met, a Friedman 
repeated measures ANOVA on ranks (non-paramet-
ric test) was performed. This study was designed to 
have 80% power of detecting a difference of 0.5 
mm between the means of all groups.
Results 
Clinical
No intraoperative complications occurred during 
surgery. All goats recovered fully after surgery, 
were standing within one day, and had a normal 
gait pattern within three days after surgery. There 
were no signs of inﬂammation, skin ulceration, or 
wound-healing problems. All bone chambers were 
strongly ﬁxed into the tibia. In most cases the bone 
chambers were surrounded by a layer of callus and 
covered with ﬁbrous tissue, irrespective of the con-
tents of the chamber. No new bone formation was 
seen at the endosteal surface of the tibial cortex.
Histology
A layer of necrotic, non-vascularized graft remnant 
was present at the top of the chamber—either with 
ﬁbrous tissue inﬁltration or only graft material as it 
was inserted. Fibrous tissue was present between 
the new bone at the bottom of the chamber and the 
graft remnant at the top of the chamber (Figure 
2a). This ﬁbrous tissue preceded the front of bone 
ingrowth. A loose mesenchymal-like tissue with 
blood sinusoids and capillaries penetrated the graft 
material. 
Newly formed bone was present in all bone 
chambers. New bone was formed by intramem-
branous ossiﬁcation, with growth upward into the 
chamber. The amount and appearance of the new 
bone varied between specimens—from young, 
woven bone surrounded by active osteoclasts to 
more mature lamellar bone with fatty marrow 
and trabeculae (Figure 2b). No resorption of the 
graft material was observed in the TCP/HA-ﬁlled 
chambers (Figure 2c). Apposition of new bone on 
the TCP/HA was observed in all TCP/HA-ﬁlled 
chambers (Figure 2d). No collagen carrier mate-
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Histomorphometry
Neither side (p = 0.6 and p = 0.1) nor position (p = 
0.9 and p = 0.2) of the chamber affected bone or 
total tissue ingrowth, respectively. There was no 
interaction between factors. The addition of OP-1 
device to allografts at either low dose (p = 0.04) 
or high dose (p = 0.02) gave increased total tissue 
ingrowth distances compared to the allograft con-
trol. The use of TCP/HA either with or without the 
addition of OP-1 device did not result in any dif-
ferences in total tissue ingrowth. However, total 
tissue ingrowth distance was signiﬁcantly less in 
the allograft control than in the TCP/HA control 
(p = 0.02).
OP-1 had no effect on bone ingrowth distance 
relative to the controls for both allografts and 
TCP/HA (Figure 3). However, high-dose OP-1 
mixed with allograft gave signiﬁcantly more bone 
ingrowth than the TCP/HA control (p = 0.004). 
Figure 2. A. Typical examples of the bone chamber content of allograft control (left) and allograft with high-dose OP-1 
(right). Graft remnants (GR) are still present in the top of the specimen. New bone (NB) formation takes place from the 
ingrowth openings upward to the top of the chamber. Fibrous tissue (FT) precedes the front of bone ingrowth. The line 
demarcates this front. Hematoxylin-eosin stained section. Magniﬁcation: 12.5×. 
B. Detail of allograft with high-dose OP-1 specimen showing newly formed bone at the bottom of the chamber. There 
were no differences in appearance of newly formed bone between the controls and either low-dose or high-dose OP-1 
specimens. Hematoxylin-eosin stained section. Magniﬁcation: ×100. 
C. Typical examples of the bone chamber content of TCP/HA control (left) and TCP/HA (TCP) with high-dose OP-1 (right). 
There are TCP/HA granules throughout the entire specimen. New bone (NB) formation takes place from the ingrowth 
openings upward to the top of the chamber. Fibrous tissue precedes the front of bone ingrowth. New bone is apposited 
on the TCP/HA granules at the bottom of the chamber. The front is again indicated by a line. Hematoxylin-eosin stained 
section. Magniﬁcation: ×12.5.
D. Detail of TCP/HA specimen with high-dose OP-1 showing new bone (NB) apposited on the TCP/HA granules (at the 
bottom of the chamber). There were no differences in appearance of newly formed bone between the controls and 






















































556 Acta Orthopaedica 2007; 78 (4): 551–558
Discussion 
Within impacted bone chips, the migration of 
cells into the impacted allograft is compromised 
and vascularization is delayed for several weeks. 
It seems, however, that delayed or reduced new 
bone ingrowth seen in experiments with impaction 
is less important and may even be beneﬁcial, as 
long as the graft/ﬁbrous tissue composite remains 
strong enough to withstand forces acting on it 
during remodeling (Tägil and Aspenberg 2001). 
In a previous study, impaction of cancellous bone 
grafts and a TCP/HA bone substitute mixed with 
OP-1 device led to reduced ﬁbrous tissue ingrowth 
as seen after 4 weeks (Hannink et al. 2006). Using 
higher doses of the OP-1 device, more collagen 
carrier material was impacted between the graft 
material, ﬁlling up the space between the impacted 
material and thereby delaying tissue ingrowth and 
remodeling. Similar observations, although not in 
the context of the impaction grafting setting, have 
been described previously by Franke Stenport and 
coworkers (2003). In addition, the volume availa-
ble for tissue ingrowth was reduced by the impac-
tion of TCP/HA particles, creating small TCP/HA 
particles between the larger ones. 
From our present ﬁndings, the previously 
observed lack of ingrowth after 4 weeks appears to 
have been a delay rather than an inhibition. After 
8 weeks, however, the delay was only partially 
overcome. Similarly to our results after 4 weeks, 
no differences in bone ingrowth between OP-1 
device groups and their controls were observed. 
However, after 8 weeks signiﬁcantly more ﬁbrous 
tissue ingrowth was measured in allografts mixed 
with OP-1 device compared to the allograft con-
trol. In contrast, after 4 weeks signiﬁcantly less 
ﬁbrous tissue was measured when comparing the 
allografts mixed with OP-1 to the allograft control 
(Hannink et al. 2006). In the TCP/HA groups, no 
differences in ﬁbrous tissue ingrowth between OP-
1 device groups and their controls were observed, 
where there was a highly signiﬁcant dose-depen-
dent decrease in ﬁbrous tissue ingrowth after 4 
weeks. An observation time of 8 weeks might still 
be too short; however, no remnants of collagen car-
rier could be seen between the impacted allografts 
or TCP/HA granules, suggesting that all the OP-1 
had been released from the carrier, thus no effect of 
the growth factor could be expected.
The data from both our previous study and the 
present work demonstrate the difﬁculty of using 
a biological enhancer of bone healing, such as an 
osteoinductive growth factor, in a situation where 
access to the blood supply and stem cells is limited 
and where bone healing is not optimal. Recently, 
Kärrholm et al. (2006) showed that mixing of OP-
1 with morselized allograft did not improve early 
ﬁxation of either the acetabular or femoral compo-
nent in revision surgery of the hip. In contrast, the 
inﬂuence of OP-1 on impacted allograft implants 
was recently investigated experimentally in loaded, 
primary, and impaired revision settings (Soballe et 
al. 2004). Under primary conditions, OP-1 reduced 
mean implant ﬁxation; in contrast, under the 
impaired healing conditions of the revision setting, 
OP-1 increased incorporation and ﬁxation of the 
implants. However, an OP-1 solution (without the 
collagen carrier) was used in that study.
The collagenous extracellular matrix of bone is 
considered an optimal delivery system for osteo-
genic proteins (Cook et al. 2005). However, prob-
ably the collagen type-I carrier is not the optimal 
carrier to use in impaction grafting. Ideally, a car-
rier should perform several important functions in 
Figure 3. Ingrowth distances of ﬁbrous tissue and bone for 
each treatment group, depicted in a box plot. The doses 
of OP-1 device included: [1] 0.83 µg OP-1 combined with 
0.24 mg collagen carrier per implant, and [2] 2.5 µg OP-1 
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addition to binding the protein (Pinholt et al. 1991); 
it should not, however, obstruct the migration of 
cells into the impacted graft or vascularization. 
This makes it interesting to compare the results 
of the present study with the results of studies in 
which OP-1 was combined with graft without a 
carrier system. In a similar bone chamber model in 
rats, using a dose similar to our lowest dose with-
out a collagen carrier (OP-1 solution) in impaction 
grafting, Tägil et al. (2000) found an increase in 
bone formation. In contrast, a study using an OP-1 
device (with collagen carrier) in combination with 
impaction grafting showed only very moderate 
effects on bone ingrowth (Lind et al. 2001). More-
over, using an OP-1 solution in a weight-bearing 
rabbit knee impaction grafting model, Tägil et al. 
(2003) showed no augmentation of morselized 
impacted bone graft incorporation.
The effects of BMPs have been shown to be con-
centration-dependent. The local concentration will 
be greatly determined by the release kinematics of 
the carrier (Takita et al. 2004). The collagen car-
riers that have been used in clinical studies effect 
an initial bulk release. Such a release may result in 
excessive bone formation at locations with favo-
rable conditions. At locations with less favorable 
conditions, however, such as within impacted bone 
grafts, the BMP clearance might be faster than the 
bone induction response of the host (Groeneveld 
and Burger 2000).
Our data again indicate that the lack of effect 
when OP-1 is used in different clinical situations 
could be related to the problem that different bio-
logical environments require different dosages of 
growth factors and carriers for optimal stimulation. 
The challenge is to ﬁnd ways to apply these drugs 
with consistent success in various applications in 
humans. 
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